Ramipril
- Generic Name
- Ramipril
- Brand Names
- Altace, Altace HCT
- Drug Type
- Small Molecule
- Chemical Formula
- C23H32N2O5
- CAS Number
- 87333-19-5
- Unique Ingredient Identifier
- L35JN3I7SJ
- Background
Ramipril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to ramiprilat in the liver and, to a lesser extent, kidneys. Ramiprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure...
- Indication
For the management of mild to severe hypertension. May be used to reduce cardiovascular mortality following myocardial infarction in hemodynamically stable individuals who develop clinical signs of congestive heart failure within a few days following myocardial infarction. To reduce the rate of death, myocardial infarction and stroke in individuals at high ...
- Associated Conditions
- Cardiovascular Events, Diabetic Nephropathy, Heart Failure, Hearth Failure With Reduced Ejection Fraction (HFrEF), Hypertension, Myocardial Infarction, Nondiabetic proteinuric chronic kidney disease, Stroke, High risk cardiovascular event
- Associated Therapies
- -
Impact of Diabetes on Left Ventricular Remodeling
- Conditions
- Interventions
- First Posted Date
- 2010-01-20
- Last Posted Date
- 2012-12-17
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 72
- Registration Number
- NCT01052272
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
Efficacy of Aliskiren Compared to Ramipril in the Treatment of Moderate Systolic Hypertensive Patients
- Conditions
- Interventions
- First Posted Date
- 2010-01-05
- Last Posted Date
- 2012-04-03
- Lead Sponsor
- Novartis
- Target Recruit Count
- 506
- Registration Number
- NCT01042392
- Locations
- 🇫🇷
Novartis Investigative Site, Witry-Les-Reims, France
🇫🇷Novartis Investigator Site, Marsilly, France
🇫🇷Investigative Site, Toulon, France
Aliskiren Versus Ramipril on Antiproteinuric Effect in Hypertensive, Type 2 Diabetic Patients With Microalbuminuria
- First Posted Date
- 2009-12-24
- Last Posted Date
- 2009-12-24
- Lead Sponsor
- University of Pavia
- Target Recruit Count
- 120
- Registration Number
- NCT01038895
- Locations
- 🇮🇹
University of Pavia, Pavia, PV, Italy
Clinical and Cost Effectiveness of ACE Inhibitor, Ramipril, in Intermittent Claudicants
- First Posted Date
- 2009-12-23
- Last Posted Date
- 2014-12-19
- Lead Sponsor
- Daniel Carradice
- Target Recruit Count
- 33
- Registration Number
- NCT01037530
- Locations
- 🇬🇧
Hull and East Yorkshire Hospitals, Hull, Yorkshire, United Kingdom
A Pharmacodynamic Study to Evaluate the Effect of a Fixed Dose Combination Pill on Blood Pressure
- First Posted Date
- 2009-10-30
- Last Posted Date
- 2012-07-26
- Lead Sponsor
- Ferrer Internacional S.A.
- Target Recruit Count
- 38
- Registration Number
- NCT01005290
- Locations
- 🇺🇸
Mount Sinai Medical Center, New York, New York, United States
Studying the Effects of Antihypertensives on Individuals at Risk for Alzheimer's
- First Posted Date
- 2009-09-21
- Last Posted Date
- 2020-08-25
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 14
- Registration Number
- NCT00980785
- Locations
- 🇺🇸
Wisconisn Alzheimer's Disease Research Center, Madison, Wisconsin, United States
Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts
- Conditions
- Interventions
- First Posted Date
- 2009-07-07
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 281
- Registration Number
- NCT00933231
- Locations
- 🇨🇦
Site CA133 Foothills Medical Centre, Calgary, Alberta, Canada
🇨🇦Site CA54 University of Alberta Hospital, Edmonton, Alberta, Canada
🇨🇦Site CA27 London Health Sciences Centre, London, Ontario, Canada
Effects of Aliskiren, Ramipril, and the Combination on Levels of Angiotensin II in Patients With Decompensated Systolic Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2009-06-18
- Last Posted Date
- 2012-07-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 123
- Registration Number
- NCT00923156
- Locations
- 🇷🇺
Novartis Investigative Site, Moscow, Russian Federation
🇷🇺Novartis Investigator Site, Moscow, Russian Federation
Effect of Renin Angiotensin System Blockade on the Fas Antigen (CD95) and Asymmetric Dimethylarginine (ADMA) Levels in Type-2 Diabetic Patients With Proteinuria
- Conditions
- First Posted Date
- 2009-05-06
- Last Posted Date
- 2009-06-03
- Lead Sponsor
- Gulhane School of Medicine
- Target Recruit Count
- 78
- Registration Number
- NCT00893425
- Locations
- 🇹🇷
Gulhane School of Medicine, Ankara, Turkey
China Medical University Hospital (CMUH) Triapin Listing
- First Posted Date
- 2009-02-11
- Last Posted Date
- 2010-08-27
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 49
- Registration Number
- NCT00841880
- Locations
- 🇨🇳
Sanofi-Aventis Administrative Office, Taipei, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.